Autologous Immunotherapy With Multi-target Gene-modified CAR-T/TCR-T Cell for Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
100 Clinical Results associated with BCMA x CD19 x CD22 x CD33 x CD38 x DR5 x EGFRvIII x MSLN x NY-ESO-1 x c-Met
100 Translational Medicine associated with BCMA x CD19 x CD22 x CD33 x CD38 x DR5 x EGFRvIII x MSLN x NY-ESO-1 x c-Met
0 Patents (Medical) associated with BCMA x CD19 x CD22 x CD33 x CD38 x DR5 x EGFRvIII x MSLN x NY-ESO-1 x c-Met